Subsequent combinatorial inhibition of mTOR and Src with Rapamycin and Dasatinib dramatically reduced A52 tumor growth and importantly, we observed activity of the mTOR and Src pathways in human HCC. Here, SRC is linked to hepatocellular carcinoma.